Baxalta Reports Positive Sales Momentum In Second Quarter Of 2015, Raises Financial Guidance For Second Half Of 2015
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today reported revenues for the second quarter and first half of 2015, which exceeded expectations, and provided its financial outlook for the third quarter and second half of 2015. The company continues to bolster its portfolio with acquisitions and collaborations focused on rare and orphan diseases, and advanced its product pipeline with the achievement of significant milestones. Baxalta launched as an independent company, listed on the New York Stock Exchange, on July 1, 2015.
“The Baxalta team is successfully executing on our strategies to build an independent, global biopharmaceutical company focused on delivering innovation that provides patients with better treatment options for challenging chronic and rare diseases,” said Ludwig Hantson, chief executive officer and president, Baxalta. “It is an exciting time for Baxalta. Our strong financial performance, increasing depth and breadth across the portfolio, progress toward near-term launches, and compelling growth prospects are differentiating our company.”
Help employers find you! Check out all the jobs and post your resume.
“The Baxalta team is successfully executing on our strategies to build an independent, global biopharmaceutical company focused on delivering innovation that provides patients with better treatment options for challenging chronic and rare diseases,” said Ludwig Hantson, chief executive officer and president, Baxalta. “It is an exciting time for Baxalta. Our strong financial performance, increasing depth and breadth across the portfolio, progress toward near-term launches, and compelling growth prospects are differentiating our company.”
Help employers find you! Check out all the jobs and post your resume.